SAR 44.55
(-9.08%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 61.33 Million SAR | 17.07% |
2022 | 52.39 Million SAR | 15.95% |
2021 | 45.18 Million SAR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 15.6 Million SAR | 0.0% |
2024 Q1 | 15.6 Million SAR | 1.34% |
2023 Q3 | 15.39 Million SAR | 0.82% |
2023 Q4 | 15.39 Million SAR | 0.0% |
2023 FY | 61.33 Million SAR | 17.07% |
2023 Q2 | 15.27 Million SAR | 0.0% |
2023 Q1 | 15.27 Million SAR | 7.86% |
2022 FY | 52.39 Million SAR | 15.95% |
2022 Q4 | 14.15 Million SAR | 0.0% |
2021 FY | 45.18 Million SAR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Middle East Pharmaceutical Industries Co. | 338.43 Million SAR | 81.877% |
Al-Dawaa Medical Services Company | 5.74 Billion SAR | 98.932% |
Nahdi Medical Company | 8.71 Billion SAR | 99.296% |
Almujtama Alraida Medical Co. | 407.73 Million SAR | 84.958% |